A study evaluating clinical impact of [18F]flutemetamol PET in a tertiary memory clinic setting in patients with uncertain diagnosis

Trial Profile

A study evaluating clinical impact of [18F]flutemetamol PET in a tertiary memory clinic setting in patients with uncertain diagnosis

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease; Dementia; Lewy body disease; Mild cognitive impairment
  • Focus Diagnostic use
  • Most Recent Events

    • 24 Aug 2017 New trial record
    • 20 Jul 2017 Preliminary results (n=61) presented at the Alzheimer's Association International Conference 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top